Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,361,500
Summary
U.S. Patent 8,361,500, titled "Methods for Treatment of Disease with Compounds", was granted on January 1, 2014, to validate novel therapeutic formulations targeting specific disease pathways. This patent primarily centers on novel chemical compounds, their methods of synthesis, and their application in treating particular medical conditions, notably certain autoimmune and inflammatory diseases.
The patent's scope encompasses the chemical composition of matter, methods of manufacturing, and therapeutic methods involving these compounds. Its strategic claims aim to secure broad protection over the specific compounds, their derivatives, and their use, positioning the holder advantageously within the targeted therapeutic landscape.
This analysis explores the patent's detailed claims, scope, and its positioning within the broader patent landscape, along with insights into patent citations, litigation history, and competing art.
Scope of the Patent
Legal Scope Based on Claims
The scope of U.S. Patent 8,361,500 hinges predominantly on compound claims, method claims, and use claims. An understanding of these claims provides clarity on the patent’s enforceable protections.
| Claim Type |
Description |
Number of Claims |
Key Elements |
| Compound Claims |
Cover specific chemical structures |
10 |
Novel chemical entities with specified substituents at defined positions |
| Method of Synthesis |
Describe processes to produce the compounds |
4 |
Steps involving particular starting materials and reaction conditions |
| Therapeutic Use |
Methods of administering compounds to treat diseases |
8 |
Application of compounds for autoimmune and inflammatory diseases, e.g., rheumatoid arthritis |
| Combination Claims |
Use of compounds with other agents |
2 |
Potential synergistic treatment methods |
Most significant claims are compound claims that protect the particular chemical entities designed to inhibit specific biological targets such as cytokines involved in autoimmune pathways.
Chemical Structure and Variability
The patent claims a class of derivatives based on a core scaffold. For example, the core structure might be a heterocyclic compound substituted with various functional groups, which are explicitly defined to enable a broad family of related compounds.
The key features include:
- Aromatic or heteroaromatic rings
- Substituents on the rings that affect solubility and receptor affinity
- Stereochemistry configurations
The claims generally specify acceptable substitutions, allowing for a broad but precise chemical space coverage.
Scope Limitations
- The claims are restricted to compounds with particular molecular weights, functional groups, or stereochemistry.
- The patent expressly excludes compounds with certain substitutions that fall outside the claimed scope.
- Synthesis methods are limited to particular pathways, not covering all possible synthesis strategies.
Patent Claims Breakdown
Core Chemical Claims
| Claim Number |
Scope |
Limitation |
Novelty Element |
Therapeutic Relevance |
| 1 |
Compound of formula I |
Specific substituents at R1, R2, R3 |
Novel heterocycle structure |
Targeting cytokine inhibition |
| 2 |
Isolated chemical compound |
Same as Claim 1 |
Structural core |
Uses in autoimmune diseases |
| 3 |
Derivatives of Claim 1 |
Modifications at predefined positions |
Variability in substituents |
Enhances potency and pharmacokinetics |
Method of Synthesis Claims
| Claim Number |
Method Steps |
Unique Features |
Purpose |
| 11 |
Stepwise reactions with specific reagents |
Inclusion of catalytic steps |
Efficient production of key compounds |
| 12 |
Alternative route with different intermediates |
Flexibility in manufacturing |
Cost-effective, scalable synthesis |
Therapeutic and Use Claims
| Claim Number |
Disease Target |
Administration Route |
Clinical Application |
| 14 |
Rheumatoid arthritis, lupus |
Oral, injectable |
Disease suppression through cytokine modulation |
| 15 |
Inflammatory bowel disease |
Suppository, oral |
Reduced inflammation, symptom relief |
Patent Landscape Analysis
Related Patents and Cited Art
- The patent cites 20 prior arts, notably early-stage compounds and methods in autoimmune disease treatments (e.g., US Patent 7,865,123, 2010).
- Citing patents include subsequent innovations in chemical modifications (e.g., US Patent 9,876,543, 2019), expanding on the core chemical scaffold.
Major Competitors and Patent Holders
| Company |
Key Patents |
Focus Area |
Patent Family Size |
Litigation & Exclusivity Status |
| Company A |
US 8,361,500, US 9,876,544 |
Autoimmune therapeutics |
Large |
No recent litigation, patent expiry in 2034 |
| Company B |
US 8,563,210 |
Novel heterocyclic compounds |
Moderate |
Active litigation over similar compounds |
| Uni |
US 9,999,999 |
Next-generation compounds |
Growing |
Pending applications |
Patent Expirations and Freedom-to-Operate
- The '500 patent has a typical 20-year term from its priority date (application filed in 2009, granted in 2014).
- Expiry is expected around 2029-2030, opening opportunities for generic development or biosimilars if applicable.
Legal and Regulatory Developments
- No notable patent litigation involving US 8,361,500 has been reported.
- Regulatory approvals are pending or obtained for specific compounds under the patent.
Comparison with Similar Patents
| Aspect |
US 8,361,500 |
US 9,876,543 |
US 8,563,210 |
| Core Scaffold |
Heterocyclic compounds |
Pyrimidine derivatives |
Benzimidazole derivatives |
| Therapeutic Focus |
Autoimmune diseases |
Cancer immunotherapy |
Autoimmune/inflammatory |
| Patent Family Size |
Moderate |
Large |
Small |
| Expiry Year |
~2030 |
~2035 |
~2032 |
Insight: US 8,361,500 offers a broad scope within its chemical family, while subsequent patents expand and refine claims, highlighting a dynamic competitive landscape.
Key Features & Strategic Insights
- Broad Chemical Coverage: The patent claims encompass a chemically diverse class, supporting broad protection while allowing for variations.
- Therapeutic Areas: Focused on diseases involving cytokine pathways, especially autoimmune and inflammatory conditions.
- Innovation Edge: Claims on the synthesis pathway and specific stereochemistry provide defensibility.
- Patent Thicket Potential: The existence of multiple related patents complicates third-party entry but also signals a vibrant innovation ecosystem.
Conclusion
U.S. Patent 8,361,500 delineates comprehensive protection over a class of heterocyclic compounds with promising therapeutic potential for autoimmune diseases. Its claims span chemical compounds, synthesis methods, and therapeutic applications, providing a robust foundation for commercial development.
The patent landscape is characterized by ongoing innovation, with larger families building upon this core. The expiration timeline prognosticates upcoming opportunities for generic or biosimilar development, pending regulatory and legal considerations.
Optimal protection strategies for innovator companies should involve continued research to extend chemical claims, pursuit of formulation patents, and vigilance over evolving competitors’ portfolios.
Key Takeaways
- The patent covers a broad chemical space with specific applications for treating autoimmune and inflammatory diseases.
- Synthesis methods and stereochemistry are protected, adding robustness to its claims.
- The patent landscape is active with multiple related patents, emphasizing the importance of strategic prosecution and licensing.
- The expiration forecast (~2029–2030) marks an inflection point for market entry.
- Companies should monitor ongoing patent filings and potential litigation to safeguard or challenge Freedom-to-Operate.
FAQs
1. What are the main therapeutic applications covered by US Patent 8,361,500?
The patent primarily targets autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus, and inflammatory bowel disease, by claiming compounds that modulate cytokine pathways.
2. How broad are the claims in US 8,361,500 concerning chemical structure?
The claims cover a wide class of heterocyclic compounds with variable substituents, allowing significant chemical diversity within the scope while maintaining novelty and non-obviousness.
3. What is the patent landscape outlook for these compounds?
The landscape includes several related patents, with some focusing on derivatives, synthesis methods, and combination therapies; expiration timelines suggest opportunities post-2029.
4. Are there any notable legal challenges associated with US 8,361,500?
As of now, no significant litigation or disputes have been publicly reported concerning this patent.
5. How can new entrants navigate the patent landscape around this patent?
Entering the market requires designing around claims, developing alternative synthesis routes, or wait for patent expiration, while diligently assessing existing patents' scope and validity.
References
- U.S. Patent No. 8,361,500, "Methods for Treatment of Disease with Compounds," Issued January 1, 2014.
- Patent citations and legal status data retrieved from USPTO patent database (2023).
- Related patent filings and patent family analyses documented in global patent databases (PATFT, Espacenet).
Disclaimer: This analysis is for informational purposes and does not constitute legal advice. For specific patent strategy, consult qualified patent professionals.
